1. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: Current progress and future directions. Blood cancer journal. 2021;11(2):1-25.

2. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood reviews. 2019;36:70-87.

3. Kirtonia A, Pandya G, Sethi G, Pandey AK, Das BC, Garg M. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. Journal of molecular medicine. 2020;98(8):1069-91.

4. Sillar JR, Germon ZP, De Iuliis GN, Dun MD. The role of reactive oxygen species in acute myeloid leukaemia. International journal of molecular sciences. 2019;20(23):6003.

5. Müller K, Oh K-W, Nordin A, Panthi S, Kim SH, Nordin F, et al. De novo mutations in SOD1 are a cause of ALS. Journal of Neurology, Neurosurgery & Psychiatry. 2022;93(2):201-6.

6. Cooper-Knock J. Implications of confirmed de novo pathogenic SOD1 mutations. BMJ Publishing Group Ltd; 2022. p. 118-.

7. Lin C-H, Vu JP, Yang C-Y, Sirisawad M, Chen C-T, Dao H, et al. Glutamate-cysteine ligase catalytic subunit as a therapeutic target in acute myeloid leukemia and solid tumors. American Journal of Cancer Research. 2021;11(6):2911.

8. Milani P, Gagliardi S, Cova E, Cereda C. SOD1 transcriptional and posttranscriptional regulation and its potential implications in ALS. Neurology research international. 2011;2011.

9. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radical Biology and Medicine. 2002;33(3):337-49.

10. Namdari S, Saadat M. Susceptibility to preeclampsia is associated with a 50-bp insertion/deletion polymorphism at the promoter region of the SOD1 gene. Journal of the Turkish German Gynecological Association. 2021;22(4):268.

11. Eisen A, Mezei MM, Stewart HG, Fabros M, Gibson G, Andersen PM. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management. Amyotrophic lateral sclerosis. 2008;9(2):108-19.

12. Milani P, Amadio M, Laforenza U, Dell'Orco M, Diamanti L, Sardone V, et al. Posttranscriptional regulation of SOD1 gene expression under oxidative stress: Potential role of ELAV proteins in sporadic ALS. Neurobiology of disease. 2013;60:51-60.

13. Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer. 2020;20(3):158-73.

14. Liu Q, Hua M, Yan S, Zhang C, Wang R, Yang X, et al. Immunorelated gene polymorphisms associated with acute myeloid leukemia. Clinical & Experimental Immunology. 2020;201(3):266-78.

15. Barzegar M, Farsan MA, Amiri V, Mohammadi S, Shahsavan S, Mirzaeian A, et al. AML-derived extracellular vesicles confer de novo chemoresistance to leukemic myeloblast cells by promoting drug export genes expression and ROS inhibition. Iranian Journal of Pharmaceutical Research: IJPR. 2021;20(1):384.

16. Broom WJ, Greenway M, Sadri-Vakili G, Russ C, Auwarter KE, Glajch KE, et al. 50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2008;9(4):229-37.

17. Cebrian A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, et al. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer research. 2006;66(2):1225-33.

18. Spisak K, Klimkowicz-Mrowiec A, Pera J, Dziedzic T, Aleksandra G, Slowik A. rs2070424 of the SOD1 gene is associated with risk of Alzheimer's disease. Neurologia i neurochirurgia polska. 2014;48(5):342-5.

19. Ebrahimpour S, Saadat I. Association of CAT C-262T and SOD1 A251G single nucleotide polymorphisms susceptible to gastric cancer. Molecular Biology Research Communications. 2014;3(4):223.